Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors

The immunotherapeutic catumaxomab targets EpCAM positive cancers and is approved for the treatment of peritoneal carcinomatosis. To assess the safety of intravenous applications a phase 1 clinical trial was initiated. Treatment of EpCAM positive tumor patients with catumaxomab caused dose dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Borlak, Jürgen, Länger, Florian, Spanel, Reinhard, Schöndorfer, Georg, Dittrich, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053709/
https://www.ncbi.nlm.nih.gov/pubmed/27058902
http://dx.doi.org/10.18632/oncotarget.8574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053709/
https://www.ncbi.nlm.nih.gov/pubmed/27058902
http://dx.doi.org/10.18632/oncotarget.8574

Ejemplares similares